Seminal anti-M  llerian hormone levels during recombinant XXXX follicle-stimulating hormone treatment in @entity1 with idiopathic infertility undergoing assisted reproduction cycles.

@entity1 @entity248
A prospective study was designed to investigate the effects of recombinant @entity1 follicle-stimulating hormone (rhFSH) on seminal anti-M  llerian hormone ( @entity248 ) levels in @entity1 with idiopathic oligoasthenoteratozoospermia (iOAT), researching possible relationships between the seminal @entity248 behavior and the response to the treatment. Thirty-nine @entity1 who were candidates for intracytoplasmic sperm injection (ICSI) because of iOAT were enrolled. @entity1 were treated on alternately days with 150  IU of rhFSH for at least 3  months before assisted reproduction cycles. Main outcome measures were seminal @entity248 concentrations before and after rhFSH therapy. After treatment, 16 subjects (responders) showed an improvement in their sperm count compared to baseline (7.6      2.9 vs. 19.3      7.7, p  <  0.01) whereas 23 @entity1 (non-responders) experienced no sperm modifications. Baseline seminal @entity248 concentrations were significantly higher in responders than in non-responders (53.0      30.6 vs. 34.6      18.5, p  <  0.025). Following therapy, a greater increase in @entity248 levels was observed in responders compared to non-responders (    =  24.8      36.4 vs.     =  6.4      11.2, p  <  0.028). Seminal @entity248 levels significantly and positively correlated with sperm count (after rhFSH treatment rho  =  0.647, p  <  0.001). Our study suggests that rhFSH improves sperm count in a quota of iOAT @entity1 , and the subjects who respond to the treatment have higher baseline seminal @entity248 concentrations than the @entity1 who are not responsive. Seminal @entity248 could be helpful to select those infertile @entity1 who may benefit from rhFSH treatment.
